LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today announced that data from its Phase 3 trial of PRX-00023, a novel long-acting 5-HT1A agonist, was featured in a poster presentation at the 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Boca Raton, Florida. The meeting is sponsored by the National Institutes of Health and the American Society of Clinical Psychopharmacology.
